Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

64.13USD
15 Dec 2017
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$64.14
Open
$64.08
Day's High
$65.29
Day's Low
$63.02
Volume
860,874
Avg. Vol
458,283
52-wk High
$99.45
52-wk Low
$35.99

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $3,143.32
Shares Outstanding(Mil.): 49.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Clovis Announces Priority Review Designation For Rucaparib Supplemental NDA

* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION

Dec 05 2017

BRIEF-Clovis Oncology reports Q3 adjusted shr loss of $1.24

* CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS

Nov 01 2017

BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib

* Clovis Oncology submits supplemental New Drug Application for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer

Oct 09 2017

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

* Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

Sep 13 2017

BRIEF-Clovis Oncology Q2 loss per share $3.88

* Clovis Oncology announces second quarter 2017 operating results

Aug 02 2017

BRIEF-Bristol-Myers, Clovis Oncology announce broad clinical collaboration

* Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types

Jul 31 2017

BRIEF-Clovis Oncology announces underwriters' option to purchase additional shares

* Clovis Oncology announces exercise in full of underwriters' option to purchase additional shares of common stock Source text for Eikon: Further company coverage:

Jun 21 2017

BRIEF-Clovis Oncology announces upsizing and pricing of public offering

* Clovis Oncology announces upsizing and pricing of public offering of common stock

Jun 20 2017

BRIEF-Clovis Oncology announces proposed offering of common stock

* Clovis Oncology announces proposed offering of common stock

Jun 19 2017

Clovis's ovarian cancer drug set for label expansion, shares soar

Clovis Oncology Inc said on Monday late-stage data on its already-approved ovarian cancer drug showed that the treatment could benefit four times as many patients, sending shares of the U.S. biotech soaring 50 percent.

Jun 19 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,895 +53.00
Pfizer Inc. (PFE.N) $37.20 +0.74
AstraZeneca plc (AZN.L) 4,881.00 -3.50
BioMarin Pharmaceutical Inc. (BMRN.OQ) $93.02 +4.49
TESARO Inc (TSRO.OQ) $80.58 -3.29
AbbVie Inc (ABBV.N) $97.45 +1.15
Novartis AG (NOVN.S) CHF83.80 -0.05
Johnson & Johnson (JNJ.N) $142.46 +0.81
Eli Lilly and Co (LLY.N) $86.54 +0.04
GlaxoSmithKline plc (GSK.L) 1,295.00 +4.50

Earnings vs. Estimates